Clinical trials
Breast Cancer Screening clinical trials
Below are recruiting breast cancer screening clinical trials, each written for real people, not researchers. We’re tracking 608 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06632886Recruiting
AI study to find cancers from your past CT scans
This study uses artificial intelligence to look at CT scans you've already had (without dye) to try and find signs of several types of cancer early. It may help find cancer sooner when it's easier to treat.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07708194RecruitingPhase 1/Phase 2
Entinostat plus pyrotinib and hormone therapy for advanced breast cancer
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07698366Recruiting
Ultrasound screening for breast cancer in older women
This study tests if ultrasound screening can help find breast cancer early in women aged 65–80 who live in the community. Participants will have an ultrasound exam to check for signs of breast cancer.
Kunshan, JiangsuAges 65–80 - NCT07678957RecruitingPhase 2
Comparing BL-M07D1 vs DS-8201 for HR-positive, HER2-low breast cancer
This trial compares a new drug, BL-M07D1, to an existing treatment (DS-8201) for women with HR-positive, HER2-low breast cancer that has come back or spread. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT07676383Recruiting
Better cancer screening with community precision navigation
This trial tests a program to help people at high risk for certain cancers get the free screening tests they need. It aims to make screening easier by providing personalized guidance in the community.
Huaihua, HunanAges 45–74 - NCT07673588Recruiting
Instagram and podcast study for breast cancer awareness in young women
This study tests whether combining Instagram posts with podcast episodes can help women aged 20-39 learn more about breast cancer and get recommended screenings. It aims to make health information easy to access and understand.
AnkaraAges 20–39 - NCT07669467RecruitingPhase 3
Nuvastatic for fatigue in triple-negative breast cancer patients
This trial tests whether Nuvastatic, a natural supplement, can help reduce fatigue in women with triple-negative breast cancer who are about to start chemotherapy. If you have stable or worsening fatigue and meet the other criteria, you may be able to join.
Visakhapatnam, Andhra PradeshAges 18–65 - NCT07651345Enrolling by invitation
Helping Women Return for Overdue Breast Cancer Screening
This study tests different ways to encourage women in Singapore to return for mammograms (breast cancer screening) if they've fallen behind. You'd be randomly assigned to receive different types of reminders or support to help you schedule your screening.
SingaporeAges 50–69 - NCT03971045RecruitingPhase 2
Pembrolizumab plus low-dose oral chemo for chest wall breast cancer
This Phase 2 trial tests pembrolizumab (an immune therapy) plus low-dose oral cyclophosphamide in people with chest wall breast cancer that has spread locally and may have distant metastases. It aims to see if this combination can shrink tumors and control cancer longer, especially in tumors with certain immune markers.
MilanAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Odense CAges 18 years+ - NCT07631052RecruitingPhase 2
Low-dose Capecitabine for High-risk Early Breast Cancer
This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.
Toronto, OntarioAges 18 years+ - NCT06452706RecruitingPhase 2
Study of TQB2102 for HER2-negative breast cancer that has spread
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
Bozhou, AnhuiAges 18–75 - NCT07616258Recruiting
Reducing follow-up visits after breast cancer treatment
This study tests whether some patients who finished curative breast cancer treatment can safely have fewer follow-up appointments and scans. Researchers want to see if less frequent monitoring is safe for patients without any signs of cancer returning.
Beaumont, DublinAges 18 years+ - NCT04985266RecruitingPhase 2
Watch blood DNA for early breast cancer return, then add palbociclib
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
AngersAges 18 years+ - NCT07592793Enrolling by invitation
Community Health Worker Perspectives on New Programs
This study asks community health center workers and partner staff about their experiences implementing a new health program. Your feedback helps researchers understand what works and what challenges exist in delivering care in community settings.
Boston, MassachusettsAges 18 years+ - NCT07586826RecruitingPhase 2
Romiplostim N01 plus ATRA for low platelets after cancer treatment
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
BeijingAges 18 years+ - NCT04590560Recruiting
Best timing for breast screening in women ages 45–49 and 70–74
This study looks at the best time interval for breast cancer screening (mammograms) for women in two age groups. The goal is to reduce missed cancers while avoiding unnecessary tests.
Meldola (FC), FCAges 45–49 - NCT07580105Recruiting
AI tool to help diagnose breast cancer from MRI scans
This study tests a new artificial intelligence software called Kenko Breast AI+ that analyzes breast MRI scans to help doctors better detect and monitor breast cancer. If you've had or are planning to have a breast MRI for cancer concerns, this trial might be right for you.
Elche, AlicanteAges 18 years+ - NCT06276868RecruitingPhase 2
Darsilide plus hormone therapy and double antibody for breast cancer
This trial tests if adding a new drug (darsilide) to standard hormone therapy and two antibodies (trastuzumab and pertuzumab) before surgery can improve outcomes for women with HR-positive, HER2-positive breast cancer that hasn't spread.
Henan, HenanAges 18–70 - NCT07557654Recruiting
Breast Cancer Detection on Chest CT Scans
This study tests whether routine chest CT scans—imaging done for other reasons—can reliably find breast cancer. Researchers will compare chest CT results with mammograms and/or breast MRI to see if this approach could catch breast cancers earlier without extra imaging.
ShanghaiAges 18 years+ - NCT07544056RecruitingPhase 2/Phase 3
BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07524322RecruitingPhase 1
RGT-490 for Advanced Cancers With PIK3CA Mutations
This study tests a new drug called RGT-490 in patients with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have a specific genetic change called a PIK3CA mutation. The drug is designed to block a protein involved in cancer cell growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07505797Recruiting
Ultrasound imaging study for suspicious breast lesions
This study is testing a new ultrasound device (ATUSA) to see how well it can image breast lesions that have been classified as suspicious (BI-RADS 4 or 5). If you have a recent finding that needs further evaluation, this research might help improve detection methods.
Sacramento, CaliforniaAges 18–94 - NCT07503717Recruiting
Brain scan surveillance in HER2-positive metastatic breast cancer
This study tests whether regular brain scans (surveillance) help spot brain metastases early in people with HER2-positive breast cancer that has spread to other parts of the body. Participation involves being randomly assigned to either routine brain scans or no extra scans to see which approach is better.
BeaumontAges 18 years+
Hear when a new Breast Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer screening?
- Yes. Clin2 currently lists 608 recruiting breast cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.